| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1831* | 2021 |
| European Respiratory Society guidelines for the management of adult bronchiectasis E Polverino, PC Goeminne, MJ McDonnell, S Aliberti, SE Marshall, ... European Respiratory Journal 50 (3), 2017 | 1052 | 2017 |
| The bronchiectasis severity index. An international derivation and validation study JD Chalmers, P Goeminne, S Aliberti, MJ McDonnell, S Lonni, J Davidson, ... American journal of respiratory and critical care medicine 189 (5), 576-585, 2014 | 983 | 2014 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 656* | 2021 |
| British Thoracic Society Guideline for bronchiectasis in adults AT Hill, AL Sullivan, JD Chalmers, A De Soyza, JS Elborn, RA Floto, ... Thorax 74 (Suppl 1), 1-69, 2019 | 517 | 2019 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 465 | 2021 |
| Etiology of non–cystic fibrosis bronchiectasis in adults and its correlation to disease severity S Lonni, JD Chalmers, PC Goeminne, MJ McDonnell, K Dimakou, ... Annals of the American Thoracic Society 12 (12), 1764-1770, 2015 | 336 | 2015 |
| Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research AT Hill, CS Haworth, S Aliberti, A Barker, F Blasi, W Boersma, ... European Respiratory Journal 49 (6), 2017 | 335 | 2017 |
| Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized … GD Perkins, C Ji, BA Connolly, K Couper, R Lall, JK Baillie, JM Bradley, ... Jama 327 (6), 546-558, 2022 | 289 | 2022 |
| Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial DJ Serisier, D Bilton, A De Soyza, PJ Thompson, J Kolbe, HW Greville, ... Thorax 68 (9), 812-817, 2013 | 285 | 2013 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 282 | 2022 |
| COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study JJ Manson, C Crooks, M Naja, A Ledlie, B Goulden, T Liddle, E Khan, ... The Lancet Rheumatology 2 (10), e594-e602, 2020 | 266 | 2020 |
| Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study MJ McDonnell, S Aliberti, PC Goeminne, MI Restrepo, S Finch, A Pesci, ... The lancet Respiratory medicine 4 (12), 969-979, 2016 | 256 | 2016 |
| Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study R Wilson, T Welte, E Polverino, A De Soyza, H Greville, A O'Donnell, ... European Respiratory Journal 41 (5), 1107-1115, 2013 | 245 | 2013 |
| Characterization of the “frequent exacerbator phenotype” in bronchiectasis JD Chalmers, S Aliberti, A Filonenko, M Shteinberg, PC Goeminne, ... American journal of respiratory and critical care medicine 197 (11), 1410-1420, 2018 | 241 | 2018 |
| Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials AF Barker, AE O'Donnell, P Flume, PJ Thompson, JD Ruzi, J De Gracia, ... The lancet Respiratory medicine 2 (9), 738-749, 2014 | 225 | 2014 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 214 | 2022 |
| Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration S Aliberti, S Masefield, E Polverino, A De Soyza, MR Loebinger, ... European Respiratory Journal 48 (3), 632-647, 2016 | 204 | 2016 |
| The EMBARC European Bronchiectasis Registry: protocol for an international observational study JD Chalmers, S Aliberti, E Polverino, M Vendrell, M Crichton, M Loebinger, ... ERJ open research 2 (1), 2016 | 195 | 2016 |
| Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience A De Soyza, G Meachery, KLM Hester, A Nicholson, G Parry, K Tocewicz, ... The Journal of Heart and Lung Transplantation 29 (12), 1395-1404, 2010 | 193 | 2010 |
James D ChalmersAsthma and Lung UK Chair of Respiratory Research, University of DundeeVerified email at dundee.ac.uk
